title: Phase II study of doxorubicin versus epirubicin in advanced breast cancer.
abstract: Doxorubicin and its epimerized analog epirubicin were tested at a dose of 75 mg/m2 given iv every 3 weeks to 42 patients with advanced breast cancer, 23 of whom were in relapse from prior cyclophosphamide, methotrexate, and 5-FU (CMF) chemotherapy. The median cumulative dose was 540 mg/m2 (range, 225-650) for doxorubicin and 565 mg/m2 (range, 150-600) for epirubicin. Complete plus partial response was documented in 11 of 21 patients (52%) following doxorubicin and in 13 of 21 patients (62%) following epirubicin. The median observation period was 22 months (range, 14-30); the median duration of response and the median survival were superimposable. Doxorubicin and epirubicin exhibited a superior response rate in previously untreated patients [six of eight (75%) vs eight of 11 (73%)] compared to those previously given CMF with or without endocrine therapy [five of 13 (38%) vs five of ten (50%)]. Vomiting, mucositis, and leukopenia were documented less frequently following administration of epirubicin as compared to doxorubicin. Regarding cardiac evaluation, no significant differences were evident between the two drugs. However, a significant fall in the left ventricular ejection fraction was documented in women who received doxorubicin following a cumulative dose greater than 550 mg/m2. Following completion of doxorubicin therapy at cumulative doses of 580 and 562 mg/m2, two women developed left ventricular failure at 6 and 14 months, respectively. Epirubicin appears to be an effective drug for the treatment of breast cancer and, given at equal doses, is less toxic than doxorubicin.
authors.forename: C
authors.initials: C
authors.lastname: Brambilla
authors.forename: A
authors.initials: A
authors.lastname: Rossi
authors.forename: V
authors.initials: V
authors.lastname: Bonfante
authors.forename: L
authors.initials: L
authors.lastname: Ferrari
authors.forename: F
authors.initials: F
authors.lastname: Villani
authors.forename: F
authors.initials: F
authors.lastname: Crippa
authors.forename: G
authors.initials: G
authors.lastname: Bonadonna
mesh_terms: D000328:Adult; D000368:Aged; D000505:Alopecia / Q000139:chemically induced; D001943:Breast Neoplasms / Q000188:drug therapy*; D004317:Doxorubicin / Q000627:therapeutic use*; D004341:Drug Evaluation; D015251:Epirubicin; D005260:Female; D006321:Heart / Q000187:drug effects; D006801:Humans; D008875:Middle Aged; D009059:Mouth Diseases / Q000139:chemically induced; D014839:Vomiting / Q000139:chemically induced
chemical_list: D015251:Epirubicin; D004317:Doxorubicin